BLB Solicitors - The Leading Chronic Pain & CRPS Solicitors
BLB Solicitors - The Leading Chronic Pain & CRPS Solicitors
  • Home
  • About Us
    • Richard Lowes
    • Bruce Dyer
    • David Gazzard
    • Andrew Atkinson
    • Clare Lowes
    • Mark Tawn
  • Pain Conditions
    • Complex Regional Pain Syndrome
    • Fibromyalgia
    • Myofascial Pain Syndrome
    • Somatic Symptom Disorder
    • Neuropathic Pain
    • Chronic Fatigue Syndrome (ME)
    • Chronic Pain Syndrome
  • Unhappy With Your Solicitor?
  • Case Studies
    • Testimonials
  • Blog
  • Contact Us
Mar 13th, 2018

First specific neuropathic pain treatment in development

The Leading Chronic Pain
& CRPS Solicitors
Rehabilitation and Treatment Richard Lowes
Nerve Cells

In a paper published in Nature Communications, researchers at the Institute for Neurosciences in Montpelier, France, have revealed the role played in causing neuropathic pain of a molecule known as FLT3. This molecule is produced in the stem cells that produce blood cells.

FLT3

Following trauma or disease, neuropathic pain may be caused by nerve lesions in the peripheral nervous system. In this recent study it was shown that immune cells contained in blood at the site of nerve lesions produce another molecule known as FL. FL then binds with and ‘switches on’ FLT3, activating a chain reaction in the nervous system, resulting in and maintaining pain.

Once the researchers understood the role played by FLT3, they were able to create an anti-FLT3 molecule which targets the site where the FL and FLT3 bind together, blocking the connection and preventing the chain reaction. Tested on mice, the symptoms of neuropathic pain were reduced within 3 hours of the anti-FLT3 molecule being administered and the effect lasted for 48 hours.

BIODOL

As a result of these findings a new company, BIODOL Therapeutics, has been formed to further develop this treatment, which would be the first specific neuropathic pain treatment to reach the market.

Whilst it remains early days, BIODOL say that following further development they will be looking “to negotiate a partnership with a pharmaceutical company for continuing clinical development to launching. BIODOL Therapeutics’ aim is to out-license its complementary programs (intra- and extracellular strategies) at the end of phases I or II of clinical trials to pharmaceutical groups able to run late stage clinical development so as to market specific NP-treatments.”

More specific detail is understandably limited at this stage, but BIODOL’s website suggests that they are looking to develop an oral formulation and that side-effects are hoped to be “limited and non-clinically significiant”.

You may also be interested in the following articles:

Those with CRPS and Chronic Pain require access to disabled toilets: what’s the law?

The good, the bad and the quacks: false hope in the treatment of CRPS and Chronic Pain

Dating with Chronic Pain and CRPS: my tips

The challenge of parenting with CRPS and Chronic Pain

Smart Crutches: an update

Contact Us

Contact Form

Left Column

Right Column

Centre

 
Sending

Recent Articles

  • The medicinal cannabis debacle: legal but unavailable
  • Ambroxol: a wonder drug for neuropathic pain?
  • New non-addictive drug may be better painkiller than morphine
  • Vitamins and supplements for Chronic Pain
  • Botox for chronic pain: how does it work and is it effective?

Share this Article

Newsletter Sign-up

* indicates required
View All Related Articles

Get in Touch Today

Contact Form

Left Column

Right Column

Centre

 
Sending

1 Edgar Buildings,
George Street,
Bath, BA1 2DU

01225 462871 01225 445060
Authorised & Regulated by Solicitors Regulation Authority (No. 636644).
©2019 BLB Solicitors  |  Privacy & Terms Created by Noisy Little Monkey